WO2024111003A1 - Dispositif de réanimation et de récupération de sang - Google Patents
Dispositif de réanimation et de récupération de sang Download PDFInfo
- Publication number
- WO2024111003A1 WO2024111003A1 PCT/IR2023/050027 IR2023050027W WO2024111003A1 WO 2024111003 A1 WO2024111003 A1 WO 2024111003A1 IR 2023050027 W IR2023050027 W IR 2023050027W WO 2024111003 A1 WO2024111003 A1 WO 2024111003A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- blood
- donor
- stage
- temperature
- injection
- Prior art date
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 151
- 239000008280 blood Substances 0.000 title claims abstract description 151
- 238000000034 method Methods 0.000 claims abstract description 20
- 230000008569 process Effects 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 25
- 239000001301 oxygen Substances 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 11
- 210000003743 erythrocyte Anatomy 0.000 claims description 9
- 230000006698 induction Effects 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000008156 Ringer's lactate solution Substances 0.000 claims description 4
- 210000000601 blood cell Anatomy 0.000 claims description 4
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 230000005672 electromagnetic field Effects 0.000 claims description 4
- 230000033228 biological regulation Effects 0.000 claims description 3
- 230000011132 hemopoiesis Effects 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 claims description 2
- 230000036760 body temperature Effects 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 239000007789 gas Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 230000005674 electromagnetic induction Effects 0.000 claims 2
- 238000009534 blood test Methods 0.000 claims 1
- -1 dialysis system Substances 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 abstract description 7
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 6
- 229940044683 chemotherapy drug Drugs 0.000 abstract description 5
- 238000012546 transfer Methods 0.000 abstract description 5
- 206010021143 Hypoxia Diseases 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 10
- 230000036541 health Effects 0.000 description 3
- 230000003716 rejuvenation Effects 0.000 description 3
- 208000019838 Blood disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 229960000182 blood factors Drugs 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229960003339 sodium phosphate Drugs 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0281—Apparatus for treatment of blood or blood constituents prior to transfusion, e.g. washing, filtering or thawing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/025—Means for agitating or shaking blood containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/32—Oxygenators without membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3623—Means for actively controlling temperature of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3627—Degassing devices; Buffer reservoirs; Drip chambers; Blood filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
- A61M2205/7545—General characteristics of the apparatus with filters for solid matter, e.g. microaggregates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/165—Filtering accessories, e.g. blood filters, filters for infusion liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/36—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests with means for eliminating or preventing injection or infusion of air into body
Definitions
- the present invention relates to medical equipment, and, more particularly, to an apparatus for direct blood transfusion.
- Chemotherapy can be impossible for some cancer patients who are too old or anemic, as their weakened blood factors may make it difficult for them to receive certain chemotherapy drugs. As a result, doctors may need to withdraw from the treatment, change the drug, or adjust its dosage, which can disrupt the proper treatment process and even pose a threat to the patient's life. It can be said that this device is designed for end-stage patients. Therefore, the effort to save these patients is worth taking the risk.
- Chemotherapy is a frequently used treatment option for many types of cancer; however, it may not be a viable option for patients with blood-related conditions. For example, elderly patients or those with blood disorders such as acute myeloid leukemia may be unable to receive chemotherapy drugs due to their weakened state. In order to solve this problem, it is crucial to enhance and prepare the patient's blood. Simply providing bag blood, even if it is labeled as fresh, is insufficient as it lacks proper oxygenation and platelet count. Therefore, there is a need to strengthen the blood to ensure it is capable of receiving chemotherapy drugs.
- vein-to-vein transfusion This involves circulating fresh, safe, and active blood in the patient's circulatory system.
- This new blood helps to purify the patient's blood, while also providing oxygen and essential factors such as platelets. It's evident that when a healthy individual's fresh and oxygenated blood enters the patient's bloodstream, it functions spontaneously by reinforcing and supporting the patient and their blood.
- the above-mentioned rubber tubes are interconnected by means of a glass tube affording a means of visual inspection of the transfusion process.
- the apparatus is provided with a vessel, containing a medicinal liquid compatible with blood.
- Additional tubes similar to the above-described ones have their free ends immersed in the vessel with the medicinal liquid. Said additional tubes as well as the tubes connected to the needles which are introduced into the blood systems of the donor.
- the known apparatuses also incorporate a distributing means, usually formed as a two-way cock, which communicates with the above-described tubes as well as with the vessel containing the medicinal liquid.
- the cock is mounted between the rubber tube connected to the needle introduced into the donor's blood system and one of the rubber tubes immersed in the vessel with the medicinal liquid.
- Blood is delivered from the donor to the recipient with the aid of a wide variety of pumps. From among the known apparatus for direct blood transfusion, the most popular variety uses the principle of continuous pumping of blood from the donor to the recipient. However, apparatus of the above-described type cannot be employed for direct blood transfusion what with the high risk of the donor being infected from the recipient carrying infectious diseases, purulent infection, septic, tuberculous, and venereal diseases, malignant neoplasms, and malignant blood disorders.
- Another system that has been worked on is a system compact enough to be located entirely beside the donor's chair, and able to process the blood while the donor is still resting in the chair after having donated the blood.
- the separated blood components may be stored in their individual optimum environments immediately after the whole blood is drawn, and the blood does not need to be transported back to a separation laboratory for processing.
- the System includes a needle (or other cannula-like device) for insertion into a vein of the donor and drawing whole blood therethrough, a rotor for holding the blood after it is drawn, and a motor for spinning the rotor so as to cause the blood to separate into components, for example, plasma and red blood cells.
- the current method for rejuvenating allogeneic blood involves a solution containing sodium pyruvate, inosine, adenine, and sodium phosphate.
- This solution increases the production of ATP and DPG -2,3 by cells while reducing the amount of potassium leakage from cells. This action leads to an increase of p50 in stored cells, a rightward deviation of the oxygen dissociation curve (ODC), and an increase in ORC.
- ODC oxygen dissociation curve
- This method of rejuvenating cells is approved by the FDA and can only be performed on packed RBC products. This process typically takes almost two hours and is performed using approved systems from COBE 2991 (TerumoBCT, Lakewood, CO, Haemonetics ACP 215, or Braintree, MA). However currently, an automatic system capable of rejuvenating one's own cells or during surgery has not been introduced.
- This invention pertains to a device for transferring blood vein-to-vein from donor to patient post-tests.
- the claimed invention consists of two general stages. The first stage is related to the donor and the second stage is related to the transfusion of blood from the donor to the receiver.
- the procedure of this system consists of two stages including 22 parts that work together for the stated task.
- Blood entering the tank A specific unit of plasma-removed blood from the blood bank that has been donated with either blood type O or the recipient's blood type enters into a sterile blood tank
- Ringer's lactate serum compound enriched with hematopoietic compounds to the blood: blood is combined with lactated ringer serum enriched with erythropoietin hormone, minerals, and vitamins effective in hematopoiesis including vitamin B12, this process leads to dilution and increase of blood volume and its enrichment in order to stimulate hematopoiesis.
- Passing through the air trap For this, the blood is passed through one or more serum microdrips and macrodrips. After that, air bubbles are trapped using a device to ensure that there are no air bubbles inside the blood.
- Blood transfusion to a donor Then, blood is injected into the person whose blood is to be collected, preferably through a central catheter.
- Controlling the donor’s symptoms The vital and sensory signs of the donor are controlled as well. It is necessary to breathe 60-99% moist oxygen while simultaneously receiving and donating blood.
- Output pressure monitor The process commences with a blood pressure monitor that measures the output blood pressure from the donor.
- Primary measurement system blood samples are separated and blood parameters are examined, tested, and evaluated, including blood oxygen level, blood sugar, and blood type, some blood health tests can be performed at this stage.
- Blood pump A a pump device is deployed to circulate the blood from the donor to the recipient. The speed of the transfusion is carefully calibrated based on the output pressure from the donor's body.
- Heparinization of blood To avoid the risk of blood clotting during the transfusion, a heparin injection device is employed.
- Passing through an electromagnetic field the blood is circulated several times through the winding tubes in the area affected by the electromagnetic field. This is done to subject the red blood cells to magnetic induction, as they contain iron. This process enhances the ability of red blood cells to absorb and store oxygen, thus preventing any loss of oxygen during the process.
- Dialysis system the process of dialysis starts. It involves the removal of toxins, excess fluids, and other waste products from the blood.
- Injection and combination of drugs tank the required medications for the patient are incorporated into the blood. The precise injection and control of drug composition into the bloodstream is also enabled.
- Oxygen and ozone injection and concentration regulation system After passing through the vibration filter, oxygen is injected into the blood, in such a way that first oxygen is mixed and dissolved in liquid or gas form in a diluting liquid such as distilled water or lactated Ringer's serum, and then the liquid containing dissolved oxygen is slowly mixed with the blood. This makes the red blood cells not lose their absorbed oxygen, restore their ability to absorb oxygen, and increase the duration of oxygen storage. With oxygen, ozone is also added
- Temperature setting blood temperature is adjusted according to normal body temperature to make it ready for injection. Blood is passed through several stages of spiral tubes that are in the vicinity of a heat induction device that works with an infrared lamp, and at the end, the blood temperature is measured using a temperature sensor, according to the analysis of data obtained from the blood temperature, the control system decides to repeat the steps or adjust the temperature of the heat induction device. Also, this system heats the blood temperature a few millidegrees higher than the blood temperature inside the body so that, taking into account the temperature loss in the blood passage, the blood has the same temperature as the body at the time of injection.
- Blood pump B In the next step, an additional pumping device is employed to guide the purified blood to the patient's body
- the final measurement system As with the primary stages, another measuring system is employed to control blood temperature, oxygen levels, and the absence of clots and air bubbles.
- the donor's blood is transferred from the donor's vein to the patient's vein through a path where the devices and systems used eliminate the problems of vein-to-vein transfer.
- Blood is preferably injected into the recipient through a Central Venous Catheter.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
Abstract
L'appareil de la présente invention est utilisé pour la transfusion sanguine directe, ainsi que pour l'introduction de divers liquides médicinaux dans le système sanguin du receveur. Il peut ne pas être une option viable pour des patients atteints d'un cancer avec des affections liées au sang. De plus, la déficience en oxygène requise dans le corps du patient ne peut être corrigée que par une transfusion sanguine directe depuis un donneur vers le receveur. Dans cette situation, il devient nécessaire de transférer le sang des veines d'un donneur à un receveur. Dans ce but, des conditions spécifiques sont nécessaires pour effectuer le processus de transfert veineux. Le présent dispositif offre des conditions pour activer la circulation de sang frais dans la circulation sanguine d'un patient. En renforçant le patient et son sang, nous pouvons créer les conditions idéales pour recevoir des médicaments de chimiothérapie, ce qui permet de traiter le cancer en toute sécurité.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IR14013006228 | 2022-11-24 | ||
| IR140150140003006228 | 2022-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024111003A1 true WO2024111003A1 (fr) | 2024-05-30 |
Family
ID=91196700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IR2023/050027 WO2024111003A1 (fr) | 2022-11-24 | 2023-11-19 | Dispositif de réanimation et de récupération de sang |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024111003A1 (fr) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020068015A1 (en) * | 2000-09-26 | 2002-06-06 | Hans-Dietrich Polaschegg | Apparatus and method for control of ultrafiltration in extracorporeal treatment of blood |
| EP1810703A1 (fr) * | 2006-01-20 | 2007-07-25 | Bellco S.r.l. | Machine de dialyse surveillant la pression artérielle par mesure de la saturation en oxygène |
| CN101053684A (zh) * | 2007-05-07 | 2007-10-17 | 赵增友 | 一种人体畜体自血循环回输臭氧消毒自动输液针具 |
-
2023
- 2023-11-19 WO PCT/IR2023/050027 patent/WO2024111003A1/fr unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020068015A1 (en) * | 2000-09-26 | 2002-06-06 | Hans-Dietrich Polaschegg | Apparatus and method for control of ultrafiltration in extracorporeal treatment of blood |
| EP1810703A1 (fr) * | 2006-01-20 | 2007-07-25 | Bellco S.r.l. | Machine de dialyse surveillant la pression artérielle par mesure de la saturation en oxygène |
| CN101053684A (zh) * | 2007-05-07 | 2007-10-17 | 赵增友 | 一种人体畜体自血循环回输臭氧消毒自动输液针具 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101332733B1 (ko) | 적혈구에 활성 성분을 내재화시키는 용해/재봉합 방법 및 장치 | |
| ES2361173T3 (es) | Máquina de tratamiento sanguíneo extracorpóreo. | |
| US20080160107A1 (en) | Use of nitric oxide gas to treat blood and blood products | |
| JPH07509645A (ja) | 透析患者の低血圧を防止するための装置及び方法 | |
| JP2003524474A (ja) | 中断されないフローポンプ装置および方法 | |
| JP2001511679A (ja) | 血液濾過システム | |
| Chang et al. | METHAQUALONE, METHYPRYLON, AND GLUTETHIMIDE CLEARANCE BY THE MICROCAPSULE ARTIFICIAL KIDNEY: IN VITRO AND IN PATIENTS WITH ACUTE INTOXICATION | |
| US20210379265A1 (en) | Method and system for controlled hyperthermia | |
| US20100189597A1 (en) | Methods and Systems for Preparing Blood Products | |
| US3699960A (en) | Parabiotic dialysis apparatus | |
| Burgert et al. | Effects of intraosseous transfusion of whole blood on hemolysis and transfusion time in a swine model of hemorrhagic shock: a pilot study | |
| WO2024111003A1 (fr) | Dispositif de réanimation et de récupération de sang | |
| EP3300748B1 (fr) | Circuits de fluides jetables pour photopherèse extracorporelle ayant une source intégrée d'agent photoactif | |
| EP1415673A1 (fr) | Dispositif utilisable pour le traitement d'hémofiltration | |
| US20210154390A1 (en) | Low volume extracorporeal photopheresis systems and methods | |
| RU2565656C2 (ru) | Способ и устройство детоксикации организма | |
| EP3381485B1 (fr) | Dispositif d'échange de plasma thérapeutique | |
| RU2363420C2 (ru) | Способ гемосорбции у собак | |
| RU72137U1 (ru) | Устройство для инфузии озонированного физиологического раствора | |
| EP4137171A1 (fr) | Systèmes et procédés permettant d'effectuer une photophérèse extracorporelle | |
| Yılmaz et al. | Does the use of infusion pumps increase hemolysis during blood transfusion in patients with thalassemia? | |
| Bazaev et al. | A wearable device for continuous automated peritoneal dialysis with dialysis− sorption regeneration of the dialysis fluid | |
| Swift et al. | Haemodialysis | |
| RU2152788C1 (ru) | Способ экстракорпоральной иммунокоррекции у детей с гнойно-септическими заболеваниями | |
| RU2043122C1 (ru) | Способ лечения сепсиса у детей раннего возраста |